Advancements in Multiple Myeloma Treatment: Frontline Approaches and Therapies for Early Relapse
Morie Gertz, MD, and Ajai Chari, MD, discuss evolving treatment paradigms, highlighting VRd as standard frontline therapy for transplant-eligible patients while noting the emerging role of quadruplet regimens (particularly daratumumab-based combinations), strong evidence for antibody-containing regimens in transplant-ineligible patients from trials like MAIA and CEPHEUS, and the promising but logistically complex role of CAR T-cell therapy in early relapsed disease.
EP. 1: Current Strategies for Frontline Therapy in Transplant-Preferred NDMM
October 29th 2024Panelists discuss how VRd (bortezomib, lenalidomide, dexamethasone) remains the standard frontline regimen for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, though some now consider adding daratumumab (dara-VRd) in high-risk cases.
EP. 2: Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials
November 5th 2024Panelists discuss how patient-specific factors like age, comorbidities, cytogenetic risk status, and personal preferences guide decisions to deviate from standard protocols, with particular attention to frailty scores and organ function when considering treatment intensity.
EP. 5: Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM
November 26th 2024Panelists discuss how the CEPHEUS trial’s demonstration of improved progression-free survival with daratumumab-VRd versus VRd alone in transplant not-preferred NDMM provides compelling evidence for quadruplet therapy in this setting, though considerations of cost, toxicity management, and patient selection remain important factors in implementation.
